

# Please join us to learn about an FDA-approved first line monotherapy option in advanced NSCLC

## Topics of discussion at this event include:

- Historical clinical trial eligibility considerations in advanced NSCLC
- Clinical evidence, safety profile, and post-hoc and exploratory analyses from one of the largest advanced NSCLC clinical trials conducted to date

## Presented by



### Eric Nadler, MD, MPP


*The US Oncology Network*

Dallas, TX

**Saturday, September 24 | 12:00 - 1:00 PM CT**

**Chicago Ballroom ABCD,  
Chicago Marriott Downtown Magnificent Mile  
Chicago, IL**

Scan QR code to add to calendar



**This presentation was approved by the IASLC as an independent activity held in conjunction with the 2022 North America Conference on Lung Cancer. *This presentation is not sponsored or endorsed by NACLC and is not part of the official IASLC accredited program.***

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, this Program is limited to U.S. Healthcare Professionals and persons with bona fide professional interest in the information presented. No CME credits are offered for attendance of this presentation.

**REGENERON**

© 2022 Regeneron Pharmaceuticals, Inc. All Rights Reserved. ONC.22.07.0016 07/22